Skip to main content
Northwestern University Feinberg School of Medicine
Adam Sonabend Lab

Publications

Below you'll find a list of recent publications from the Sonabend Lab and its collaborators. For a more comprehensive list, please visit Sonabend's PubMed listing.

  1. Habashy KJ, Dmello C, Chen L, Arrieta VA, Kim KS, Gould A, Youngblood MW, Bouchoux G, Burdett KB, Zhang H  et al.  Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma.  Clin Cancer Res  2024 Apr 15;30(8):1619-1629. doi:10.1158/1078-0432.CCR-23-2367
  2. Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, Chen L, Park CH, Kazi HA, Dmello C  et al.  ARF4-mediated retrograde trafficking as a driver of chemoresistance in GBM.  Neuro Oncol  2024 Mar 20;. pii:noae059
  3. Carpentier A, Stupp R, Sonabend AM, Dufour H, Chinot O, Mathon B, Ducray F, Guyotat J, Baize N, Menei P  et al.  Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.  Nat Commun  2024 Feb 23;15(1):1650. pii:1650
  4. Moscona-Nissan A, Habashy KJ, Arrieta VA, Sonabend AM, Dmello C  Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.  Oncotarget  2024 Feb 08;15:117-122. doi:10.18632/oncotarget.28549
  5. Pandey S, Cholak ME, Yadali R, Sosman JA, Tetreault MP, Fang D, Pollack SM, Gnjatic S, Obeng RC, Lyerly HK  et al.  Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond.  Cancers (Basel)  2024 Jan 23;16(3). pii:475
  6. Arrieta VA, Duerinck J, Burdett KB, Habashy KJ, Geens W, Gould A, Schwarze JK, Dmello C, Kim KS, Saganty R  et al.  ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.  Clin Cancer Res  2024 Jan 17;30(2):379-388. doi:10.1158/1078-0432.CCR-23-1889
  7. Romay MC, Knutsen RH, Ma F, Mompeón A, Hernandez GE, Salvador J, Mirkov S, Batra A, Sullivan DP, Procissi D  et al.  Age-related loss of Notch3 underlies brain vascular contractility deficiencies, glymphatic dysfunction, and neurodegeneration in mice.  J Clin Invest  2024 Jan 16;134(2). pii:e166134
  8. Hou D, Wan H, Katz JL, Wang S, Castro BA, Vazquez-Cervantes GI, Arrieta VA, Dhiantravan S, Najem H, Rashidi A  et al.  Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma.  Front Immunol  2023;14:1295218. pii:1295218
  9. Najem H, Arrieta VA, Duffy J, Tripathi S, Zannikou M, Dhiantravan S, Miska J, McCortney K, Steffens A, Walshon J  et al.  Prohibitin Expression in Antigen-Presenting Cells: Implications for Inciting Trigger in CNS IgG4-Related Disease.  Ann Case Rep  2024;9(1). pii:1607
  10. Fares J, Petrosyan E, Kanojia D, Dmello C, Cordero A, Duffy JT, Yeeravalli R, Sahani MH, Zhang P, Rashidi A  et al.  Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.  J Clin Invest  2023 Dec 15;133(24). pii:e161142
  11. Nandoliya KR, Khazanchi R, Winterhalter EJ, Youngblood MW, Karras CL, Sonabend AM, Micco AG, Chandler JP, Magill ST  Validating the VS-5 Score for Predicting Outcomes After Vestibular Schwannoma Resection in an Institutional Cohort.  World Neurosurg  2023 Aug;176:e77-e82. doi:10.1016/j.wneu.2023.04.123
  12. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H  et al.  Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.  Nat Med  2023 Jun;29(6):1370-1378. doi:10.1038/s41591-023-02347-y
  13. Gould A, Gonzales VAA, Dmello CC, Saganty R, Lukas RV, Zhang DY, Heimberger AB, Canney M, Carpentier A, Desseaux C  et al.  Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas.  Adv Oncol  2023 May;3(1):77-86. doi:10.1016/j.yao.2023.01.017
  14. Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G  et al.  Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial.  Lancet Oncol  2023 May;24(5):509-522. doi:10.1016/S1470-2045(23)00112-2
  15. Sachdev S, Dmello C, Sonabend AM  Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.  Clin Cancer Res  2023 May 01;29(9):1648-1650. doi:10.1158/1078-0432.CCR-23-0018
  16. Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU  et al.  Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment.  Mol Cancer Res  2023 May 01;21(5):389-396. doi:10.1158/1541-7786.MCR-22-0920
  17. Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, Ellingwood A, Han Y, Lopez-Rosas A, Zannikou M  et al.  STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.  Nat Commun  2023 Mar 23;14(1):1610. pii:1610
  18. Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P  et al.  Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.  Nat Commun  2023 Mar 22;14(1):1566. pii:1566
  19. Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM  et al.  IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.  J Immunother Cancer  2023 Feb;11(2). pii:e006239
  20. Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM  Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.  J Clin Invest  2023 Jan 17;133(2). pii:e163447
  21. Sita TL, Gopalakrishnan M, Rooney MK, Ho A, Savoor R, Sonabend AM, Tate MC, Chandler JP, Lesniak MS, Kruser TJ  et al.  Mean Brain Dose Remains Uninfluenced by the Lesion Number for Gamma Knife Stereotactic Radiosurgery for 10+ Metastases.  World Neurosurg  2022 Sep;165:e380-e385. doi:10.1016/j.wneu.2022.06.057
  22. Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RV  Next Steps for Immunotherapy in Glioblastoma.  Cancers (Basel)  2022 Aug 20;14(16). pii:4023
  23. Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J  et al.  Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.  Clin Cancer Res  2022 Jul 15;28(14):3156-3169. doi:10.1158/1078-0432.CCR-21-2563
  24. Larkin CJ, Arrieta VA, Najem H, Li G, Zhang P, Miska J, Chen P, James CD, Sonabend AM, Heimberger AB  Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era.  Front Immunol  2022;13:907605. pii:907605
  25. Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A  et al.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.  JCI Insight  2022 May 09;7(9). pii:e157612
  26. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2022 Mar;3(3):373. doi:10.1038/s43018-022-00343-8
  27. Arrieta VA, Najem H, Petrosyan E, Lee-Chang C, Chen P, Sonabend AM, Heimberger AB  The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.  Int J Mol Sci  2021 Dec 13;22(24). pii:13382
  28. Gould A, Zhang D, Arrieta VA, Stupp R, Sonabend AM  Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas.  Oncotarget  2021 Dec 07;12(25):2474-2475. doi:10.18632/oncotarget.28018
  29. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2021 Dec;2(12):1372-1386. doi:10.1038/s43018-021-00260-2
  30. Zhang DY, Gould A, Happ HC, Youngblood MW, Dmello C, Kang SJ, Canney M, Stupp R, Carvill GL, Sonabend AM  Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner.  Neurooncol Adv  2021;3(1):vdab165. pii:vdab165
  31. Gonzalez-Buendia E, Zhao J, Wang L, Mukherjee S, Zhang D, Arrieta VA, Feldstein E, Kane JR, Kang SJ, Lee-Chang C  et al.  TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.  Clin Cancer Res  2021 Oct 15;27(20):5669-5680. doi:10.1158/1078-0432.CCR-21-0312
  32. Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC  et al.  Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.  Lancet Oncol  2021 Aug;22(8):1103-1114. doi:10.1016/S1470-2045(21)00245-X
  33. Moreno-Jiménez S, Alegría-Loyola MA, Sonabend AM, Romano SK, Romo CG  Management of glioblastoma: a perspective from Mexico.  Chin Clin Oncol  2021 Aug;10(4):44. doi:10.21037/cco-20-129
  34. Zhang DY, Singer L, Sonabend AM, Lukas RV  Gene Therapy for the Treatment of Malignant Glioma.  Adv Oncol  2021 May;1:189-202. doi:10.1016/j.yao.2021.02.016
  35. Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER  et al.  Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.  Clin Cancer Res  2021 Mar 15;27(6):1766-1777. doi:10.1158/1078-0432.CCR-20-1499
  36. Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R  et al.  A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.  Sci Transl Med  2021 Mar 10;13(584). pii:eabb3945
  37. Sonabend AM, Stupp R, Lee-Chang C, Okada H  Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy.  Oncotarget  2021 Jan 05;12(1):8-9. doi:10.18632/oncotarget.27865
  38. Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, Jusué-Torres I, Xiao T, Arrieta VA, Zhang DY  et al.  Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.  J Exp Med  2021 Jan 04;218(1). pii:e20200913
  39. Youngblood MW, Stupp R, Sonabend AM  Role of Resection in Glioblastoma Management.  Neurosurg Clin N Am  2021 Jan;32(1):9-22. doi:10.1016/j.nec.2020.08.002
  40. Kinslow CJ, Rae AI, Neugut AI, Adams CM, Cheng SK, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Iwamoto FM  et al.  Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma.  Br J Neurosurg  2020 Dec;34(6):690-696. doi:10.1080/02688697.2019.1710820
  41. Kam KL, Brooker SM, Mao Q, Barnea Slonim L, Yaseen NR, Brat DJ, Sonabend AM, Lukas RV  Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system.  J Clin Neurosci  2020 Nov;81:61-64. doi:10.1016/j.jocn.2020.09.014
  42. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.  Neuro Oncol  2020 Oct 14;22(10):1425-1438. doi:10.1093/neuonc/noaa154
  43. Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY  et al.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.  Clin Cancer Res  2020 Sep 01;26(17):4699-4712. doi:10.1158/1078-0432.CCR-19-4110
  44. Kane JR, Zhao J, Tsujiuchi T, Laffleur B, Arrieta VA, Mahajan A, Rao G, Mela A, Dmello C, Chen L  et al.  CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.  Clin Cancer Res  2020 Aug 15;26(16):4390-4401. doi:10.1158/1078-0432.CCR-19-3104
  45. Awah CU, Chen L, Bansal M, Mahajan A, Winter J, Lad M, Warnke L, Gonzalez-Buendia E, Park C, Zhang D  et al.  Ribosomal protein S11 influences glioma response to TOP2 poisons.  Oncogene  2020 Jul;39(27):5068-5081. doi:10.1038/s41388-020-1342-0
  46. Garton ALA, Kinslow CJ, Rae AI, Mehta A, Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce JN  et al.  Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.  J Neurosurg  2020 May 08;134(5):1357-1367. doi:10.3171/2020.2.JNS192767
  47. Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C  et al.  Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.  Clin Cancer Res  2020 Jan 15;26(2):477-486. doi:10.1158/1078-0432.CCR-19-2182
  48. Shah PV, Arrieta VA, Lee-Chang C, Sonabend AM  Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.  J Cell Immunol  2020;2(6):352-358. doi:10.33696/immunology.2.066
  49. Rooney MK, Golden DW, Byun J, Lukas RV, Sonabend AM, Lesniak MS, Sachdev S  Evaluation of patient education materials for stereotactic radiosurgery from high-performing neurosurgery hospitals and professional societies.  Neurooncol Pract  2020 Jan;7(1):59-67. doi:10.1093/nop/npz031
  50. Arrieta VA, Iwamoto F, Lukas RV, Sachdev S, Rabadan R, Sonabend AM  Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?  J Neurosurg  2019 Dec 06;132(5):1667-1672. doi:10.3171/2019.9.JNS192523